The Proteomics Facility provides a comprehensive suite of proteomics services to the Cancer Center membership. The primary emphasis is to provide expert consultation and state-of-the-art technologies operating at maximum performance at affordable costs to Cancer Center members. This is quite challenging because unlike genomics, proteomics technologies are highly varied; there are not consensus optimal approaches for most problems, and instruments, software and analytical strategies continue to evolve rapidly. Therefore, equipment and analytical methods must be continually updated. As a result, most of the instruments in the Facility were purchased within the past grant period, which includes $1.3 million invested in 2008 alone to replace obsolete mass spectrometers with 2 LTQ Orbitrap mass spectrometers and a high sensitivity triple quadropole mass spectrometer. Sensitivity of protein identifications has increased more than 100-fold over the past grant period through a combination of method optimization, acquisition of more sensitive instruments and development of an improved data analysis pipeline. Other methods have been similarly improved and new complementary methods have been implemented. The facility is also beginning to implement quantitative protein profile comparisons on LC-MS/MS based analyses using several complementary approaches, which will be expanded during the next grant period. During the past grant period (2003-present), 19 CC members used the Proteomics Facility and additional members benefited because many projects were collaborative between multiple CC investigators. CC members receive priority in sample analysis, substantial discounts on user fees (35-50% depending upon the service), more extensive consultation, training and assistance, and early access to methods/technologies not yet implemented as routine services. In the current year CCSG support covered 27% of non-equipment operating costs and will cover 23% of operating costs during the first year of the proposed grant. During 2007 44% of facility usage was by peer-reviewed CC members, and over the entire past grant period (2003-present) 61% of facility usage was by peer-reviewed CC members.

Public Health Relevance

Proteomics can only be accomplished as a facility because of the expense of the instrumentation and expertise needed for their operation. Proteomics offer the hope of identifying biomarkers for the early detection of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112

Showing the most recent 10 out of 685 publications